|Day's range||5.66 - 5.98|
In the latest trading session, Abbott (ABT) closed at $102.14, marking a -1.83% move from the previous day.
Abbott (ABT) study analyzes primary safety and efficacy endpoints in the first 300 people enrolled across 55 centers in the United States, Canada and Europe.
Inquiry by US regulator focuses on whether manufacturers colluded in relation to programme for low-income families
Yahoo Finance health care reporter Anjalee Khemlani discusses the ongoing investigation by the FTC of baby-formula makers, including Abbott Laboratories, Perrigo, and Nestle, on suspected collusion.
The FTC is looking into whether the companies "engaged in collusion or coordination with any other market participant regarding the bidding," according to the document. The Wall Street Journal was first to report the probe. According to the document, in 2022 the FTC began looking into potential collusion or coordination in bids to provide formula for the U.S. Department of Agriculture's Women, Infants and Children (WIC) program that provides free formula to low-income families.
Abbott (ABT) notes that using TactiFlex catheter can lead to reduced procedure times and better safety compared to the company's previous generation catheters.
Abbott's (ABT) latest approval adds to its line-up of remote patient management and treatment tools that can support doctors more effectively.
Abbott (ABT) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
NEW YORK (Reuters) -A New York City woman sued Abbott Laboratories on Monday, accusing the healthcare company of misleading consumers into believing its PediaSure nutrition drinks were "clinically proven" to increase children's height. In a proposed class action filed in Manhattan federal court, Joanne Noriega said she bought PediaSure Grow & Gain vanilla and strawberry drinks for her eight-year-old grandson, who was "short for his age," believing they would help him get taller. The Bronx resident said that by February, after a year of two PediaSure drinks per day, her grandson was still short for his age and had become "so overweight" that she stopped buying the drinks.
Abbott's (ABT) latest additions to Diversity in Clinical Trials effort expand upon the alliances, awards and the emphasis on diverse participation in its own clinical trials.
Investors are optimistic about Abbott (ABT) on continued growth in the core Diagnostics arm.
Abbott (ABT) continues to make good progress, increasing manufacturing production and recovering market share in the Nutrition business.
Cigna's (CI) first-quarter 2023 results indicate a strong contribution to revenues from Evernorth Health Services and Cigna Healthcare businesses. Management currently expects adjusted EPS to be a minimum of $24.70 in 2023.
Berkshire Hathaway, Tesla, JPMorgan Chase, Abbott Laboratories and Comcast are included in this Analyst Blog.
Acadia Healthcare's (ACHC) Q1 results reflect higher revenue per patient day, partly offset by an elevated cost level. Management reaffirms its 2023 business guidance.
A poorly received first-quarter earnings report has investors wondering if this stock's best days are behind it.
If you're looking to grow your $1,000, you can do that by investing in stocks that probably will deliver share performance. Let's check out two top Dividend Kings to buy now. You may know of Abbott because of its enormous COVID-19 testing business.
Abbott Laboratories (NYSE: ABT) has had a volatile couple of years. It benefited from COVID-related tests boosting its sales, but last year it ran into manufacturing issues that affected its baby formula production and hurt sales in its nutritional segment. The business is now getting back to normal, but the problem is that its valuation still needs to come down significantly before it's a worthwhile buy.
Centene's (CNC) first-quarter 2023 results grapple with higher operating expenses, partly offset by an expanding customer base. Management presently expects adjusted EPS to be at least $6.40 in 2023.
There's nothing quite as nasty a surprise as seeing one of your investments slash its dividend. Abbott Laboratories (NYSE: ABT) is among the most solid dividend stocks out there. As one of the largest healthcare businesses in the world, with a vast and heavily diversified base of revenue, it isn't too hard to appreciate why it could make for a decent and fairly safe investment.
Dividend growth investing is among the most common investing strategies around, and for good reason: Buying quality businesses and dividend growth stocks often go hand in hand. With at least 50 consecutive years of payout growth, Dividend Kings are the most reliable dividend growers in the investment universe. Abbott Laboratories (NYSE: ABT) has delivered 51 consecutive years of dividend growth to its shareholders.
Abbott Laboratories (NYSE: ABT) stock recently popped up in response to a first-quarter earnings report that was much better than investors had been expecting. Shares of Abbott climbed about 18% over the past month. Is Abbott Laboratories still a good dividend stock to buy following its recent run-up?
HCA Healthcare's (HCA) first-quarter results gain from increased patient admissions. Management expects EPS within the $17.25-$18.55 band this year, higher than the previous view of $16.40-$17.60.
Thanks to good quarterly results reported by two peers, Medtronic (NYSE: MDT) stock did very well on Tuesday. Medtronic didn't have any news of its own to report but didn't need to. Both Intuitive Surgical (NASDAQ: ISRG), a maker of next-generation robots for surgical procedures, and Abbot Laboratories (NYSE: ABT), a traditional pharmaceutical company that has a thriving business in devices, released their latest quarterly earnings reports after market hours on Monday and on Tuesday morning, respectively.
Double-digit organic growth in Diabetes Care, Structural Heart, Heart Failure and Neuromodulation contributed to Abbott's (ABT) Q1 revenues.